Treace Medical Q3 revenue $45.1M (+11%), net loss improves to ($15.4M), launches Nanoplasty MIS system

TREACE MEDICAL CONCEPTS, INC.

2024-Q3 EPS reported -$0.89 revenue$140,649,000

Revenue $45.1M (+11% YoY); net loss improved to ($15.4M) or ($0.25)/share from ($17.5M) loss in Q3 2023.
Adjusted EBITDA loss narrowed 45% to ($5.1M) from ($9.2M) in Q3 2023.
First entry into osteotomy market with Nanoplasty 3D Minimally Invasive Bunion Correction system; second MIS platform planned later in Q4.
Filed patent infringement suit to protect Lapiplasty technology; patent portfolio now 67 U.S. patents.
FY2024 revenue guidance revised to $204M-$211M (was $201M-$211M); expects Adjusted EBITDA loss to halve YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.